This meeting draws together international experts to discuss current techniques and research involved in cellular and molecular pathology. This year focuses on four specific areas:

- Progress in Molecular and Cellular Pathology
- Developments in immunohistochemistry for diagnostic cellular pathology
- Biomarkers
- Histopathology and Cytopathology 2014: Advances in research and techniques

With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking regarding pathology. This meeting gathers together workings from clinical, academic and pharmaceutical organisations.

This event has CPD accreditation

www.regonline.co.uk/Path2014
## Contents

**Program Outline** .................................................................................................................. 6

**Day 1: Progress in Molecular and Cellular Pathology** .......................................................... 6

  **Session Chair:** Dr Anthony (Tony) Warford, ....................................................................... 6

**Day 2: Developments in immunohistochemistry for diagnostic cellular pathology** .............. 6

  **Session Chair:** .................................................................................................................. 6

**Day 3: Morning Session: Biomarkers** .................................................................................... 6

  **Morning Session Chair:** Gaynae Badalian-Very ................................................................. 6

**Afternoon session: Histopathology and Cytopathology: Advances in research and techniques** ... 7

**Agenda** .................................................................................................................................. 8

### Day 1: Progress in Molecular and Cellular Pathology ............................................................ 8

**Introduction by the Chair.** ..................................................................................................... 8

  **MicroRNAs and the contribution of cellular pathology to understanding their role in health and disease.** 8

  **Update in the molecular pathology of uveal melanoma.** ................................................... 8

  **Oral presentations** .............................................................................................................. 8

**THE TUMOUR-STROMA RATIO (TSR) ADDITIONAL TO THE TNM CLASSIFICATION?** .......... 8

  **From Eustachius to Schuknecht: What have human temporal bone pathology studies taught us?** 8

  **Procurement Time of Human Tissue Biospecimens—Significant increases reported using AQIX® RS-I fluid technology.** 8

  **Discussion session** ............................................................................................................ 8

  **Whole Slide Imaging using Hamamatsu NanoZoomer Slide Scanner** ................................. 8

  **Oral presentations** .............................................................................................................. 8

**EXPERIENCES WITH THE LATEST GENERATION in situ HYBRIDISATION METHODOLOGIES** ...... 8

  **What can NGS offer to the cancer pathologist?** ................................................................ 8

  **Quantifying digital pathology in a large human brain cohort.** ........................................... 8

### Day 2: Developments in Immunohistochemistry for diagnostic cellular pathology .................. 9

**Introduction by the Chair.** ..................................................................................................... 9

  **Emerging role of the pathologist and cancer biomarking in as applied to stratified medicine and targeted therapy.** 9

  **Dying for a Tan’- immunocytochemistry in the assessment of photo damage and malignant melanoma.** 9

  **Oral Presentations** .............................................................................................................. 9

**EVIDENCE OF MTOR ACTIVITY DURING HUMAN SALIVARY GLAND ATROPHY** .................. 9

  **Molecular expression profiles of different types of thyroid carcinomas.** .............................. 9

  **Application of the Nanotechnology in Immunohistochemical Staining Procedures** .......... 9

  **Session Break** .................................................................................................................... 9

  **Discussion Session** .......................................................................................................... 9

  **No Antibody? No Problem.** .............................................................................................. 9

  **D-Sight, The full automated platform to analyze both nuclear and membrane Immunostaining. EGFR and Ki-67 quantification in pancreas pathologies.** 9

  **The application of fluorescent confocal microscopy in corticosteroid-insensitive diseases.** ... 9

### Day 3: Morning Session: Biomarkers ......................................................................................... 10
Discussion Sessions

Day 3: Afternoon Session: Histopathology and Cytopathology: Advances in research and techniques

Introduction by the Chair: ................................................................. 10
Pediatric Liver Tumors. Pearls and Pitfalls......................................... 10
Histopathologic diagnosis in the era of new and old yeast infections in critical ill surgical patients ............................................... 10
14:45 – 14:55 APPLICATION OF DIGITAL CYTOLOGY FOR GYNECOLOGICAL CYTOLOGY - GEORGIAN EXPERIENCE................................. 10
14:55 – 15:05 TANYCYTIC EPENDYMOMA: PRESENTATION OF A RARE CYSTIC DISEASE VARIANT AND REVIEW OF LITERATURE ...................... 10
A New Age of Breast Cancer Diagnostics: Prognosis and Treatment Implications of Simultaneous Testing of Tumors and Cancer Stem Cells ..................................................... 10
Role of cytopathology in steering targeted therapies in lung oncology patients .............................................................. 10
Using array tomography to study synapse degeneration in human brain ................................................................. 10

About the Speakers ................................................................. 11

Day 1.................................................................................................. 11
Sarah E. Coupland, ........................................................................ 11
Panos Dimitriadis, .......................................................................... 11
Douglas Rees, ............................................................................... 11
Sterghios Moschos, ....................................................................... 12
Atticus H Hainsworth, ................................................................. 12

Day 2.................................................................................................. 12
Guy Edward Orchard, .................................................................... 12
Monika Lamba Saini ...................................................................... 12
Weiming Xu .................................................................................. 12
Speaker to be confirmed, .............................................................. 12
Niccola Funel, ............................................................................... 12
Amir Hakim, ................................................................................ 13

Day 3.................................................................................................. 13
Yao-Shan Fan, ............................................................................... 13
Agata Sobczyńska - Malefora ......................................................... 13
Aline M.A. Martins, ....................................................................... 13
Paola Di Carlo .............................................................................. 13
SuEllen Pommier, .......................................................................... 14
Harman Sekhon ........................................................................... 14
Tara L Spires-Jones, ...................................................................... 14
Session breaks ................................................................. 14
Lunch .................................................................................. 14
  • All the chicken in our lunch buffet is Halal ................................................................. 14
  • We have a number of dishes that are gluten free ............................................................... 14
  • We have a range of vegetarian dishes which are separated from the meat and fish dishes ................................................................. 14
Frequently asked questions about our events ...................................................................... 14
  Is the delegate list available? ............................................................................................. 14
  Can I have the speakers slides? .......................................................................................... 14
  How can I keep up to date with Euroscicon Events? ........................................................ 15
  I don’t want my photograph on any Euroscicon promotional material ................................ 15
  Is there WIFI? .................................................................................................................... 15
  Can I have a CPD certificate? ............................................................................................ 15
Program Outline

Day 1: Progress in Molecular and Cellular Pathology
This session will discuss current topics presented by experts in their fields of research and practice. Placed in the context of molecular cellular pathology presentations will explore disease mechanisms, clinical advances and latest technology breakthroughs.

Session Chair: Dr Anthony (Tony) Warford, Senior Lecturer in Cellular Pathology, University of Westminster, UK
Anthony (Tony) Warford expertise is in molecular histopathology. He has set up and managed laboratories in the UK health service, academic institutions, biotechnology and Pharmaceutical companies. Technology developments he has spearheaded include the introduction of diagnostic immunohistochemical methods, validation of antibodies for use as biomarkers, production of probes and methods for in situ hybridisation and supervision and interpretation of GLP tissue based safety studies of potential therapeutic antibodies. Concurrently he has championed quality assurance programmes in histopathology and automation of immunohistochemistry coupled with image capture and analysis. He has also run laboratory safety and human bio-banking programmes. He has published in these fields and shared experience with fellow scientists by organising wet workshops, chairing symposia and lecturing in many countries.

Day 2: Developments in immunohistochemistry for diagnostic cellular pathology
Developments in Immunohistochemistry (IHC) techniques and technology to aid the improvements needed to boost and strengthen the use of IHC in future diagnostic pathology practice will be discussed

Session Chair: Professor Bharat Jasani, Cardiff University School of Medicine, Institute of Cancer & Genetics, UK
Professor of Oncological Pathology, internationally recognised quality assurance and standardisation of cancer biomarker analyses as UKNEQAS Breast Cancer Module Leader, member of International Working Group on Standardisation of Breast Cancer Biomarking. International Advisor to the United States Sub-Committee on Quality Assurance for Immunocytotoxicity, and Consultant and Key Opinion Leader to leading biotech companies. Principal Investigator and Co-investigator for several major translational research projects on predictive biomarkers for colorectal and breast cancer. Co-Awardee for Best National Health Innovation Award for 2007, for development of gene chip based intra-operative method for sentinel lymph node breast cancer metastases. Over 200 peer reviewed articles.

Day 3: Morning Session: Biomarkers
Identifying biological and physiological entities associated with disease are taking an increasingly important place at the tables of drug discovery and personalised medicine. Their discovery in biosamples requires the combined use of genomics, proteomics and bioinformatics platforms. Whilst for their application, robust techniques combining exquisite sensitivity and specificity must be developed. This conference is focused on technologies that are driving advances in this area and their application at gene and expression level in solid and fluid biosamples. As such this session is targeted to provide leading edge information to researchers within the academic, biotechnology and pharmaceutical sectors.

Morning Session Chair: Gaynae Badalian-VERY is a leading physician of the world and the CEO of a startup focusing on personalized medicine. Dr. Badalian-VERY has attended Semmelweis University and Harvard medical school. Dr. Badalian-VERY is continuously speaking in international meetings and has been the chair on International drug discovery and science technology in Haiku China. Dr Badalian-VERY has won several grants and award from various societies (Histiocytosis (150,000), Claudia Adam Barr (250,000)) for breakthrough research on Langerhans cell histiocytosis. She has won several recognitions on leadership, and strategy development as well. Dr. Badalian-VERY continues her attempt on bringing translational science to population base application.
Afternoon session: Histopathology and Cytopathology: Advances in research and techniques
Drawing together international experts to discuss the need for technical-based updates in the areas of immunohistochemistry, clinical and research based histopathology and in situ hybridisation.

Afternoon Session Chair: Consolato Sergi, Professor of Pathology and Adj. Professor of Pediatrics, University of Alberta, Canada
# Day 1: Progress in Molecular and Cellular Pathology

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 – 10:15</td>
<td>Exhibitions open</td>
<td>Registration and Refreshments</td>
</tr>
<tr>
<td>10:15 – 11:00</td>
<td><strong>Introduction by the Chair</strong></td>
<td><strong>MicroRNAs and the contribution of cellular pathology to understanding their role in health and disease</strong> by Dr. Anthony (Tony) Warford, Senior Lecturer in Cellular Pathology, University of Westminster, UK</td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td><strong>Update in the molecular pathology of uveal melanoma</strong></td>
<td>Professor Sarah Coupland, Professor and Honorary Consultant in Pathology, University of Liverpool, UK</td>
</tr>
<tr>
<td>11:30 – 11:45</td>
<td><strong>Oral presentations</strong></td>
<td><strong>THE TUMOUR-STROMA RATIO (TSR) ADDITIONAL TO THE TNM CLASSIFICATION?</strong> by W.E. Mesker, G.W. van Pelt, V.T.H.M Smirne, J. Morreau, J.H.M. van Krieken, R.A.E.M. Tollenaar, Departments of Surgery (1) and Pathology (2), LUMC, Leiden and Department of Pathology, UMCN, Nijmegen (3), The Netherlands</td>
</tr>
<tr>
<td>11:45 – 12:15</td>
<td><strong>Session Break</strong></td>
<td>Speakers' photo, Refreshments, Poster viewing, Sponsors exhibition</td>
</tr>
<tr>
<td>12:15 – 12:45</td>
<td><strong>From Eustachius to Schuknecht: What have human temporal bone pathology studies taught us?</strong></td>
<td>Panos Dimitriadis, Luton and Dunstable Hospital, UK</td>
</tr>
<tr>
<td>12:45 – 13:15</td>
<td><strong>Procurement Time of Human Tissue Biospecimens – Significant increases reported using AQIX® RS-I fluid technology</strong></td>
<td>Dr. Douglas Rees PhD MRSNZ, Founder, Director &amp; CSO, AQIX Ltd, London BioScience Innovation Centre, UK</td>
</tr>
<tr>
<td>13:15 – 14:15</td>
<td><strong>Session Break</strong></td>
<td>Lunch, Poster viewing, Sponsors exhibition</td>
</tr>
<tr>
<td>14:15 – 14:45</td>
<td><strong>Discussion session</strong></td>
<td></td>
</tr>
<tr>
<td>14:45 – 15:15</td>
<td><strong>Whole Slide Imaging using Hamamatsu NanoZoomer Slide Scanner</strong></td>
<td>Dr Matthew Burke, Hamamatsu Photonics UK Limited, Hertfordshire, UK</td>
</tr>
<tr>
<td>15:15 – 15:45</td>
<td><strong>Session Break</strong></td>
<td>Refreshments, Last poster viewing, Last Sponsors exhibition</td>
</tr>
<tr>
<td>15:45 – 16:00</td>
<td><strong>Oral presentations</strong></td>
<td><strong>EXPERIENCES WITH THE LATEST GENERATION in situ HYBRIDISATION METHODOLOGIES</strong> by Paul Murdock, Stemgent-Asterand, Orchard Road, Royston Hertfordshire, SG8 5HJ</td>
</tr>
<tr>
<td>16:00 – 16:30</td>
<td><strong>What can NGS offer to the cancer pathologist?</strong></td>
<td>Dr Sterghios Moschos, Redear in Industrial Biotechnology and Biochemistry; Director, Westminster Genomic Services, Department of Biomedical Sciences, University of Westminster, UK</td>
</tr>
<tr>
<td>16:30 – 17:00</td>
<td><strong>Quantifying digital pathology in a large human brain cohort</strong></td>
<td>Dr Atticus H Hainsworth, Stroke &amp; Dementia Research Centre, St George's University of London, UK</td>
</tr>
<tr>
<td>17:00</td>
<td><strong>Chairman's Summing Up</strong></td>
<td>Close of Session</td>
</tr>
</tbody>
</table>
### Day 2: Developments in Immunohistochemistry for diagnostic cellular pathology

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 – 10:15</td>
<td>Exhibitions open</td>
<td>Registration and Refreshments</td>
</tr>
<tr>
<td>10:15 – 10:45</td>
<td>Introduction by the Chair</td>
<td><strong>Professor Bharat Jasani</strong>, Cardiff University School of Medicine, Institute of Cancer &amp; Genetics, UK</td>
</tr>
<tr>
<td></td>
<td>Emerging role of the pathologist and cancer biomarking in as applied to stratified medicine and targeted therapy</td>
<td></td>
</tr>
<tr>
<td>10:45 – 11:15</td>
<td>Dying for a Tan¹'-immunocytochemistry in the assessment of photo damage and malignant melanoma.</td>
<td><strong>Dr Guy Edward Orchard</strong>, Consultant Grade Biomedical Scientist/ Laboratory Manager, St. John's Institute of Dermatology, London</td>
</tr>
<tr>
<td>11:15 – 11:30</td>
<td>Oral Presentations</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>EVIDENCE OF MTOR ACTIVITY DURING HUMAN SALIVARY GLAND ATROPHY</strong></td>
<td><strong>S Borzorgi¹, R Henley-Smith² &amp; Gh Carpenter¹</strong></td>
</tr>
<tr>
<td></td>
<td>Salivary Research Unit, Kings College London Dental Institute, UK.</td>
<td><strong>¹Salivary Research Unit, Kings College London Dental Institute, UK.</strong></td>
</tr>
<tr>
<td></td>
<td>KHP Head and Neck Biobank, Guy's and St Thomas' trust, UK</td>
<td><strong>²KHP Head and Neck Biobank, Guy’s and St Thomas’ trust, UK</strong></td>
</tr>
<tr>
<td>11:30 – 12:00</td>
<td>Session Break</td>
<td>Speakers’ photo, Refreshments, Poster viewing, Sponsors exhibition</td>
</tr>
<tr>
<td>12:00 – 12:30</td>
<td>Molecular expression profiles of different types of thyroid carcinomas.</td>
<td><strong>Dr. Monika Lamba Saini</strong>, Université catholique de Louvain, Brussels, Belgium</td>
</tr>
<tr>
<td>12:30 – 13:00</td>
<td>Application of the Nanotechnology in Immunohistochemical Staining Procedures</td>
<td><strong>Dr Weiming Xu</strong>, CEO London Biotech Ltd and Department of Molecular Biology and Biotechnology, University of Sheffield, UK</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>Session Break</td>
<td>Lunch, Poster viewing, Sponsors exhibition</td>
</tr>
<tr>
<td>14:00 – 14:55</td>
<td>Discussion Session</td>
<td></td>
</tr>
<tr>
<td>15:25 – 15:55</td>
<td>Session Break</td>
<td>Refreshments, Last poster viewing, Last Sponsors exhibition</td>
</tr>
<tr>
<td>15:55 – 16:25</td>
<td>D-Sight, The full automated platform to analyze both nuclear and membrane Immunostaining, EGFR and Ki-67 quantification in pancreas pathologies</td>
<td><strong>Dr Niccola Funel</strong>, University of Pisa, Division of Surgical Pathology, Pisa, Italy</td>
</tr>
<tr>
<td>16:25 – 16:55</td>
<td>The application of fluorescent confocal microscopy in corticosteroid-insensitive diseases</td>
<td><strong>Dr Amir Hakim</strong>, Imperial College London and Royal Brompton Hospital, London, UK</td>
</tr>
<tr>
<td>16:55 – 17:00</td>
<td>Chairman’s Summing Up</td>
<td>Close of Session</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker(s)</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>09:30 – 10:00</td>
<td>Exhibitions open</td>
<td>Registration and Refreshments</td>
</tr>
<tr>
<td>10:00 – 10:45</td>
<td>Morning Session: Biomarkers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction by the chair</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Implementation of personalized medicine into clinical pathology practice</td>
<td>Dr Gaynae Badalian-Very, Dana Farber Cancer Institute, Harvard Medical School, USA</td>
</tr>
<tr>
<td>10:45 – 11:15</td>
<td>Companion diagnostic tests for targeted cancer treatment: advances and challenges</td>
<td>Professor Yao-Shan Fan, University of Miami Miller School of Medicine, Florida, USA</td>
</tr>
<tr>
<td>11:15 – 11:45</td>
<td>Session Break</td>
<td></td>
</tr>
<tr>
<td>11:45 – 12:15</td>
<td>Diagnosing vitamin B12 deficiency using static and functional markers</td>
<td>Dr Agata Sobczyńska-Malefora, Viapath, St. Thomas’ Hospital, London, UK</td>
</tr>
<tr>
<td>12:15 – 12:45</td>
<td>Screening Serum Biomarkers on Cancer Patients: Using Mass Spectrometry to Answer Clinical Questions</td>
<td>Professor Aline M.A. Martins Translational Medicine UDF - University Center of the Federal District - Health Science SEP/SULEQ704 / 904 Conj.A - Brasilia / DF University Hospital - HUWC/UFC / Surgery Department Prof. Costa Mendes, 1608 - 3° Andar - Fortaleza – CE Brazil</td>
</tr>
<tr>
<td>12:45 – 13:30</td>
<td>Session Break</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lunch, Poster viewing, Sponsors exhibition</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 3: Afternoon Session: Histopathology and Cytopathology: Advances in research and techniques</td>
<td></td>
</tr>
<tr>
<td>13:30 – 14:15</td>
<td>Introduction by the Chair:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pediatric Liver Tumors. Pearls and Pitfalls</td>
<td>Professor Consolato Sergi, Professor of Pathology and Adj. Professor of Pediatrics, University of Alberta, Canada</td>
</tr>
<tr>
<td>14:15 – 14:45</td>
<td>Histopathologic diagnosis in the era of new and old yeast infections in critical ill surgical patients</td>
<td>Assistant Professor Paola Di Carlo, Department of Sciences for Health Promotion and Mother-Child Care, University of Palermo, Italy</td>
</tr>
<tr>
<td>14:45 – 15:05</td>
<td>Oral Presentations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>APPLICATION OF DIGITAL CYTOLOGY FOR GYNECOLOGICAL CYTOLOGY - GEORGIAN EXPERIENCE</td>
<td>E. Kldiashvili Tbilisi, Georgia (South Caucasus)</td>
</tr>
<tr>
<td></td>
<td>TANYCYTIC EPENDYMOMA: PRESENTATION OF A RARE CYSTIC DISEASE VARIANT AND REVIEW OF LITERATURE</td>
<td>F.M. Ippen, R. Pfannl, R. Rojas, A. Mahadevan, E.M. Kasper Franziska Maria Ippen, Schlossberg 21, Germany; Ekkehard Kasper, MD, PhD, FAANS, Boston, MA 02115 USA</td>
</tr>
<tr>
<td>15:05 – 15:30</td>
<td>Session Break</td>
<td>Refreshments, Last poster viewing, Last Sponsors exhibition</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>A New Age of Breast Cancer Diagnostics: Prognosis and Treatment Implications of Simultaneous Testing of Tumors and Cancer Stem Cells</td>
<td>Dr SuEllen Pommier, Associate Professor, Oregon Health &amp; Science University, USA</td>
</tr>
<tr>
<td>16:00 – 16:30</td>
<td>Role of cytopathology in steering targeted therapies in lung oncology patients</td>
<td>Dr Harman Sekhon, University of Ottawa, Ontario, Canada</td>
</tr>
<tr>
<td>16:30 – 17:00</td>
<td>Using array tomography to study synapse degeneration in human brain.</td>
<td>Dr Tara L. Spires-Jones, Reader and Chancellor’s Fellow, The University of Edinburgh, UK</td>
</tr>
<tr>
<td>17:00</td>
<td>Chairman’s Summing Up</td>
<td>Close of Meeting</td>
</tr>
</tbody>
</table>
About the Speakers

Day 1

**Sarah E. Coupland**, MBBS, PhD, is a senior pathologist at the Royal Liverpool University Hospital, and Professor and Academic Lead of Pathology at the University of Liverpool. She is the lead pathologist in Ocular Oncology, which receives patients and tumour specimens from all over the world, and she heads a team of nine students and scientists as chair of the Liverpool Ocular Oncology Research Group (www.loorg.org), which she established together with Prof. B Damato. She is also the lead hematopathologist in the region, Director of the Liverpool Tissue Bank of the Royal Liverpool University Hospital, and Deputy Head of the Dept of Molecular and Clinical Cancer Medicine. Prof. Coupland has given more than 90 invited lectures around the world, with several of these presentations being prestigious keynote lectures. Prof. Coupland has published more than 140 scientific articles, with at least 68 of these as first or senior author, with an H-index of 28. This is in addition to 16 textbook chapters. Her major scientific achievements include devising the first TNM staging system for ocular adnexal lymphomas; developing a novel grading system for malignancy of in situ conjunctival melanomas; revitalizing the European Ophthalmic Oncology Group; and successfully translating molecular typing of uveal melanoma from a research tool into routine clinical practice.

**Panos Dimitriadis**, is one of the ENT-themed Core Surgical Trainees of the East of England Deanery. He trained in Athens and completed a Masters degree in otology at the UCL Ear Institute, London. His research project was on human temporal bone pathology for which he was awarded a distinction. His temporal bone pathology studies have been presented in prestigious international conferences and published in peer-review journals. His career aim is to work as an otologist in an academic centre of excellence and set up a strong TB histopathology network that would improve understanding and treatment of ear pathologies.

**Douglas Rees**, PhD MRSNZ, Founder, Director & CSO, AQIX Ltd, London BioScience Innovation Centre, UK

Douglas Rees became an Elected Member of the New York Academy of Sciences in 1981 for research studies published (1972-4) on motor nerve terminal metabolism during his Rockefeller Post-Doctoral Fellowship at the University of California (1970-73). In 1973-78 he was appointed Muscular Dystrophy Research Fellow, tenable in the Institute of Neurology, Southern General Hospital, Glasgow, where the development of AQIX® RS-I was initiated using human cadaver nerve-muscle tissue biopsies. In 1978 he was appointed Senior Lecturer in Neurophysiology, Wellington Clinical School and Victoria University, New Zealand. He became Head of Research & Development and Consultant Physiologist of Res-Del Ltd, New Zealand (1980). His contribution to organ preservation research over two decades and appointment as Patron of the New Zealand Muscular Dystrophy Association in 1988, led to his election as a Member of the Royal Society of New Zealand in 1997. He incorporated Res-Del International Ltd (now Aqix Ltd) into the UK in December 1999.

**Matthew Burke**, PhD, received his doctorate qualification from Newcastle University in 2013 in neuropathology of vascular dementia supervised by Professor Raj Kalaria. During training he specialised in varying imaging techniques and analysis including confocal microscopy and stereology. He has published a number of peer reviewed papers in high impact journals including Neuropathology and Applied Neurobiology. Since completing his qualifications, Matthew has joined Hamamatsu Photonics UK where he works exclusively in providing digital pathology solutions to leading clinicians, researchers and commercial companies with Hamamatsu’s NanoZoomer slide scanning range and associated software e.g. NDP.View2 and NDP.Analyse. He has helped to oversee the response to the increase in demand for the digital pathology market across the UK and Ireland by providing a number of presentations, workshops and demonstrations which have seen a significant amount of new installations of NanoZoomers in leading institutes over the last 12 months.
Sterghios Moschos, Redear in Industrial Biotechnology and Biochemistry; Director, Westminster Genomic Services, Department of Biomedical Sciences, University of Westminster, UK
Dr. Moschos FRSC MSB is the director of Westminster Genomic Services, a contract research service provider at the University of Westminster engaged in biomarker and diagnostic development projects. He previously lead oligonucleotide therapeutics and biomarkers research at the Sandwich site of Pfizer Ltd. after developing an international reputation as an RNA Rx and Dx expert at the NHLI, Imperial College. His work has accelerated the development of a first-in-class RNAi gene therapy for HCV, the identification of novel RNA regulators in asthma and lung inflammatory disease and the demonstration of needle-free dosing opportunities for systemic nucleic acid treatments.

Atticus H Hainsworth, is a Senior Lecturer in Cerebrovascular Disease in the Stroke & Dementia Research Centre at St George’s University of London. His first degree is in Pharmacology (Cambridge) and his PhD in Physiology & Biophysics (Rush Med Center-Chicago). Atticus has extensive experience of research in brain disease. His research group focuses on cerebral small vessel disease, which is the primary cause of lacunar stroke and vascular dementia.

Day 2

Guy Edward Orchard, Consultant Grade Biomedical Scientist/ Laboratory Manager, St. John’s Institute of Dermatology, London. Guy is actively involved in teaching and training both within the Guy’s and St. Thomas’ Trust framework but also as an external lecturer at several Universities throughout the country for students studying for MSc’s in biomedical science. Guy completed his Fellowship to the Institute of Biomedical Science (IBMS) in Cellular Pathology in 1990 having gained the highest pass in the UK across all disciplines. Guy completed his Master’s in immunology at Surrey University gaining a distinction in 1995 and achieved he’s PhD in 2010. He has worked at St. John’s for nearly his entire working career, now spanning over 25 years service. Guy received chartered scientist recognition in 2005 and is the deputy chief examiner in Cellular Pathology for the IBMS.

Monika Lamba Saini, MD (Pathology), DNB, currently works at the Department of Anatomie Pathologie, Cliniques Saint Luc, Université catholique de Louvain, Brussels, Belgium. After receiving her undergraduate medical training (MBBS) and masters degree (MD) in Pathology from India, she worked as an assistant professor in the department of pathology at the Kempegowda Institute of Medical Sciences, Bangalore, India. In 2009, she joined a molecular pathology fellowship at the Université catholique de Louvain, Brussels, where she is working on a PhD based on molecular profiling of different types of thyroid carcinoma. She is a member of professional organizations like ASCO, EORTC Head and Neck Group, and ESMO. She is also the author, co-author and peer reviewer of many national and international scientific publications. She is also the recipient of ‘National fund for scientific research, Belgium’ fellowship for her PhD.

Weiming Xu is the Chief Executives Officer in London Biotech Ltd. He obtained his PhD degree from the Imperial Cancer Research Fund/Chinese Academy of Sciences program in London. His first postdoctoral training was with Sir Bruce Ponder University of Cambridge. He then worked in Babraham Institute and later has taken the Senior Research Fellow position in the University College London, working on nitric oxide signaling with Sir Salvador Moncada. From 2009, he moved to the University of Sheffield as a Senior Research Associate. He has published more than 50 scientific papers in peer-reviewed journals with over 1,400 citations (ISI).

Speaker to be confirmed, Advanced Cell Diagnostics, Inc

Niccola Funel, University of Pisa, Division of Surgical Pathology, Pisa, Italy
Niccola Funel received his first graduation in Bio-Molecular Science from Pisa University, Italy, where he acquired both PhD graduation in “Experimental and Molecular Oncology” and Specialization in “Clinical Pathology”. Since 2002 He have been working in Surgical Pathology division (Department of Surgery, University of Pisa) where he involved in different projects focused on Pancreatic Ductal AdenoCarcinoma (PDAC). In 2010 He became PI of his project
regarding “News therapeutic strategies against PDAC”. In 2011 He is council member of Italian Society for Pancreas Study (AISP) for three years. He received a grant as “Young Investigator 2013” from “Fondazione Veronesi”, Milan, Italy. Field of expertize: PDAC, Oncology, Biomarkers, TMA, Laser Microdissection and Primary cell cultures.

Amir Hakim, Imperial College London and Royal Brompton Hospital, London, UK
Amir Hakim is a Research Associate within the Airways Disease Section at the National Heart and Lung Institute (NHLI), Imperial College London. Amir is an Assembly Board Member of the European Respiratory Society and a trainee member of the American Thoracic Society. He was recently awarded an international scholarship award for his ground breaking research into corticosteroid insensitivity by the American Thoracic Society and the National Emphysema Foundation, USA. Amir completed his PhD at NHLI, Imperial College London following a Masters programme at the University of Oxford.

Day 3

Yao-Shan Fan, MD, PhD. Professor of Pathology, Director of Cytogenetics and Molecular Diagnostic Laboratory at University of Miami Miller School of Medicine, Miami, USA. Dr. Fan’s clinical and research interests include cytogenetics and molecular diagnosis of human cancers and developmental disorders. He served as a member of the editorial board for the Encyclopedia of Medical Genomics and Proteomics; member of Cytogenetics Committee, Canadian College of Medical Geneticists, Chair of the Genetics Committee of the Quality Management Program, OMA, Canada; and President of Association of Chinese Geneticists in America. He authored a book, Molecular Cytogenetics and about 100 publications in peer-reviewed scientific journals.

Agata Sobczyńska-Malefora is a Principal Clinical Scientist at The Human Nutristasis Unit (Viapath, St. Thomas’ Hospital, London). She joined the Unit in 2000, improving and developing analytical methods including methylmalonic acid (marker of vitamin B12 deficiency). Her collaborative work with the Russian Institute of Haematology and Transfusion, St. Petersburg, investigating hyperhomocysteinemia in patients with thrombosis influenced her research interests in the direction of one carbon metabolism. In 2010 she completed a PhD in Medicine (King's College of London) investigating hyperhomocysteinemia and B vitamins status in patients receiving oral anticoagulants. Her current research focuses on the diagnostic utility of static and functional markers for vitamin B12 and folate. She is particularly interested in one carbon metabolism in relation to cardiovascular and Alzheimer's disease and diseases which affect the absorption of B vitamins. She has been a Member of The Royal Society of Chemistry and Alzheimer’s Society since 2000, and The Association for Clinical Biochemistry since 2003.

Aline M.A. Martins, Translational Medicine, UDF - University Center of the Federal District - Health Science SEP/SUL EQ704 / 904 Conj.A - Brasilia / DF
University Hospital - HUWC/UFC / Surgery Department Prof. Costa Mendes, 1608 - 3° Andar - Fortaleza – CE, Brazil
Doctor Degree in Biotechnology (Cancer Functional Proteomics GD/CNPq grant). PhD thesis was developed at Surgery Department (Liver Transplantation Center, University Hospital HUWC/UFC) under supervision of Dr. Odorico Moraes (M.D.) and Dr. Huygens Garcia (M.D.) and the experimental work was performed at University of Siena (UNISI) Italy, under supervision of Dr. Luca Bini (PDEE/Capes grant). Nowadays, works in the area of Translational Medicine, with serum biomarkers on HCC patients; molecular events of tumor microenvironment (cirrhosis), progression of hepatocellular carcinoma (HCC) and transplantation biomarkers. Develops a Post-Doc work (PD)/CNPq grant) within the area of serum biomarkers in HCC using mass spectrometry, at University Hospital (HUWC/UFC).

Paola Di Carlo is a Medical Researcher with adult patient care responsibilities “Paolo Giaccone” Polyclinic University Hospital Infectious Diseases Unit, c/o Viale Del Vespro 147 – 90147 Palermo. In-patient and day hospital patient management; outpatient Infectious Disease Clinic for the management of HIV and opportunistic infections. Consultant in surgical units. Goal-oriented research: multi-drug resistant micro-organism infections in cancer and surgical
SuEllen Pommier, Associate Professor, Oregon Health & Science University, USA
Dr. Pommier is a Research Associate Professor in the departments of Surgery, and Medical and Molecular Genetics at Oregon Health & Science University. As a geneticist, Dr. Pommier’s research focuses on determining the genetic abnormalities associated with the transformation of normal stem/progenitor cells into cancer stem/progenitor cells. She believes that these changes give breast cancer the selective advantage to initiate and support tumor proliferation.

Harman Sekhon, is an American Pathology Board certified cytopathology and is a Director of Cytopathology services and consultant for pulmonary pathology at The Ottawa Hospital, Ottawa, Canada. His research interests are lung cancer pathogenesis and molecular targets including the role nicotine acetylcholine receptors in non-neuronal normal and neoplastic lung cells. He has published more than 50 original articles in high impact journals and book chapter.

Tara L. Spikes-Jones, Reader and Chancellor’s Fellow, The University of Edinburgh, UK
Spikes-Jones’ research focuses on the mechanisms and reversibility of cognitive decline in neurodegenerative diseases and normal ageing. She completed a DPhil at the University of Oxford followed by postdoctoral research at Massachusetts General Hospital and Harvard Medical School where she stayed as Instructor then Assistant Professor for 7 years. At the University of Edinburgh, Dr Spikes-Jones currently uses high-resolution imaging techniques in disease models and postmortem human brain tissue to study synapse degeneration.

Discussion Sessions
The discussion sessions are an opportunity for informal questions and answers. This is an ideal opportunity to get advice and opinion from experts in this area. This session is not for questions about specific talks, which can be asked after the speakers’ session, but for discussing either general topics or specific issues.

Session breaks
All breaks and registrations will take place in the exhibition area where there will be lunch and refreshments.

Please try to visit all the exhibition stands during this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you.

Lunch
- All the chicken in our lunch buffet is Halal
- We have a number of dishes that are gluten free
- We have a range of vegetarian dishes which are separated from the meat and fish dishes

Frequently asked questions about our events

Is the delegate list available?
Yes this is available to everyone who attends the event and our sponsors. It is available in real time. To access the list please just log into your registration details or use the QR code on right of the agenda card which is provided on the day of the event. You will not be included in this list if you have opted out and you can do this by logging into your registration details. This list will not be sold or ever give out to third parties.

Can I have the speakers slides?
We cannot give out the slides from our speaker’s presentations as they are deleted immediately after each event. If you require a particular set of slides please approach the speaker. We will however have a meeting report and you will be emailed when this report is published.
How can I keep up to date with Euroscicon Events?
To keep updated on our events and other Life Science News, please sign up for our newsletter at www.eurosciconnews.com

I don’t want my photograph on any Euroscicon promotional material
Please let our tech person know

Is there WIFI?
Yes, please ask registration for log in details

Can I have a CPD certificate?
CPD certificates will be available in the exhibition hall after lunch

Please remember that EuroSciCon is a small independent company with no subsidies from society memberships or academic rates for venues. We try to be as reasonably priced as possible and our delegate rates are substantially lower than comparable commercial meeting organisations

Euroscicon Ltd UK, Company Number: 4326921, Trading Address: Euroscicon Ltd, Highstone House, 165 High Street, Barnet, Herts. EN5 5SU, UK